Showing posts with label ARV. Show all posts
Showing posts with label ARV. Show all posts

Sunday, 16 September 2018

Novel method for dating 'hibernating' HIV strains

Researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) and Simon Fraser University (SFU), in partnership with University of British Columbia (UBC) and Western University, have developed a novel way for dating "hibernating" HIV strains, in an advancement for HIV cure research in the province. Published in the Proceedings of the National Academy of Sciences (PNAS), the BC-CfE's first major scientific contribution to the area of HIV cure research confirms that dormant HIV strains can persist in the body for decades.

"If you can't identify it, you can't cure it. This research provides further essential clues in the pursuit of an HIV cure -- which will ultimately require the complete eradication of dormant or 'latent' HIV strains," said Dr. Zabrina Brumme, Director, Laboratory with BC-CfE and lead author on the study. "Scientists have long known that strains of HIV can remain essentially in hibernation in an individual living with HIV, only to reactivate many years later. Our study confirms that the latent HIV reservoir is genetically diverse and can contain viral strains dating back to transmission."

 
"The BC-CfE has consistently been a national and global leader on research on HIV and on the implementation of its pioneering Treatment as Prevention® strategy. The addition of molecular biologist Dr. Zabrina Brumme as Director of the innovative BC-CfE Laboratory ensures the BC-CfE will play a significant role in HIV cure research," said Dr. Julio Montaner, Director of the BC-CfE. "Curative strategies will need to address this new study's key findings. I want to acknowledge the study participants and thank them for helping to increase our knowledge on the origins of the latent HIV reservoir."

"By creating family trees of viruses using a technique called molecular phylogenetics, we can reconstruct the evolutionary history of HIV within a person," said Brad Jones, a Ph.D. student with UBC at the BC-CfE and the first author on the study. "In essence, we created a highly calibrated 'time machine' that gives us a specific time stamp for when each dormant HIV strain originally appeared in a person."

Dormant HIV strains, which have integrated their DNA into that of the body's cells, can persist for years and are unreachable by antiretroviral treatments and the immune system. They can reactivate at any time, which is why HIV treatment needs to be maintained for life.

Through advances in antiretroviral therapy, an individual living with HIV can now live a longer, healthier life on treatment. Treatment works by stopping HIV from infecting new cells. On sustained treatment, individuals can achieve a level of virus that is undetectable by standard blood tests. An undetectable viral load means improved health and that the virus is not transmittable to others -- the concept behind Treatment as Prevention®.

"Previous research had already revealed that the HIV reservoir was genetically complex. With our method, we can now understand that complexity with greater granularity, pinpointing exactly when each unique HIV strain originally appeared in a person," said Dr. Jeffrey Joy, Research Scientist at the BC-CfE and co-author on the study.

"In order to eradicate HIV from a person's body, you first need to know the characteristics of HIV in the latent reservoir," said Dr. Art Poon, Assistant Professor in Pathology and Laboratory Medicine at Western University, also a co-author on the study. "We are providing a method for better measuring the timeline of virus latency and evolution within an individual living with HIV."

In order to "date" dormant HIV strains within the viral reservoir, researchers needed to compare these strains to those that evolved within an individual living with HIV over the entire history of their infection. The BC-CfE is one of a handful of institutions worldwide capable of such research, thanks to its maintenance of a historical repository of blood specimens from individuals diagnosed with HIV in BC. These specimens date back to 1996 and were originally collected for viral load and drug resistance testing. The BC-CfE Laboratory has provided HIV drug resistance genotyping for virtually all Canadian provinces and territories since 1998, as well as for many countries worldwide.

This research was funded by the Canadian Institutes of Health Research (CIHR) in partnership with the Canadian Foundation for AIDS Research (CANFAR) and the International AIDS Society (IAS) through its support of the Canadian HIV Cure Enterprise (CanCURE), as well as the US National Institutes of Health (NIH) through its support of the Martin Delaney BELIEVE Collaboratory.

To be a speaker at STD 2018 Conference being held at Toronto, Canada, submit your abstracts here: https:/std-hiv-aids.cmesociety.com/abstract-submission 
 

Monday, 6 August 2018

Study shows how HIV is shielded from Immune Attack


Scientists from UNSW Sydney and the UK have discovered that the human immunodeficiency virus (HIV) hijacks a small molecule from the host cell to protect itself from being destroyed by the host's immune system.

The finding, as well as details of the new strategy that enabled it, are published as back-to-back papers in eLife. They identify a new target for antiviral therapy against HIV and provide a method for testing and measuring new drugs designed to target the capsid.
UNSW Ph.D. student Chantal Márquez is involved in both studies and is the first author of the paper describing the new method.

HIV forms a protein shell—called a capsid—that shields its genetic material from host defence mechanisms as it enters the cell and makes its way to the nucleus to establish infection.



Using a new single-molecule microscopy technique—developed at UNSW's Single Molecule Science in the Faculty of Medicine—the research teams found that HIV specifically incorporates a small molecule from the host cell—inositol hexakisphosphate—to strengthen its capsid. The host inadvertently provides the key for the virus infecting it to lock down the protective shell, keeping the genetic cargo safe until it is released into the nucleus.

"The HIV capsid falls apart within minutes once it's isolated from the virus," said Associate Professor Till Böcking, who led the UNSW team involved in both studies.

"Our strategy lets us study exactly how a native capsid breaks apart in real-time without taking it out of the viral membrane."

With the help of Associate Professor Stuart Turville of the Kirby Institute, the team engineered viruses with fluorescent tags to monitor the viral capsid using fluorescence microscopy.

"We can now see the effect of different molecules on the capsid, and pinpoint precisely when it cracks open and begins to collapse," says Associate Professor Böcking.

"Capsids need to be much more stable inside a cell because the infection process takes hours, not minutes—so we wanted to find out what keeps it stable inside a cell," says Dr. David Jacques of Single Molecule Science, who is an author of both studies.

The researchers found that inositol hexakisphosphate, which is abundantly present inside mammalian cells, makes the capsid much stronger, stabilizing it for 10-20 hours.

"It's like a switch. When you bind this molecule, you stabilize the capsid, and release the molecule to open it up," explains Associate Professor Böcking.

"The HIV capsid has been intensively studied, but the question of how it can simultaneously be both stable and poised to 'uncoat' has been one of the great unanswered questions in HIV biology," says Dr. Leo James, leader of the research team at the Medical Research Council Laboratory of Molecular Biology in Cambridge, UK.

Most of the currently approved HIV therapies target enzymes needed at different stages of the virus' life cycle, but none of them are directed at the HIV capsid. New drug alternatives could improve the treatment of HIV with reduced toxic effects.

Source: https://medicalxpress.com/news/2018-07-hiv-shielded-immune.html

Wednesday, 25 July 2018

STD 2018: Scientific Sessions

Session 1: Types of STDs
Sexually transmitted diseases (STDs) are infectious diseases that are transmitted from a person to another through sexual contact or blood of an infected person. The pathogens such as bacteria, virus, fungi, protozoa are responsible for the disease transmission. Bacterial STDs are Syphilis, Gonorrhoea, Chlamydia, Chancroid. Viral STDs include HIV/AIDS, Human papillomavirus, Hepatitis, Genital Herpes. Trichomoniasis is a STD caused by parasitic protozoan. Candidiasis is considered to be an fungal STD which is spread by fungus Candida albicans. Most of the sexually transmitted diseases such as viral STDs have no cure but the disease can be controlled with proper treatment while bacterial, fungal and protozoan STDs can be cured with antifungals and antibiotics.
  • Bacterial STDs
  • Viral STDs
  • Protozoan STDs
  • Fungal STDs

Session 2: Evolution of STDs
The evolution of the STD pathogens are caused by the selective pressures of the host-immune response, modern drugs, vaccines or by microbial competition. Through evolutionary phase, a pathogen can become more or less virulent. The phylogeny, epidemiology and origin studies on sexually transmitted diseases provides valuable data on the genetic transition traits in both host and pathogen. The evolutionary study of the disease-causing pathogen provides the disease transmission and diversity among the human population. The clinical epidemiologyand phylogenetic study paves way for new insights for the development of drugs and therapies against the multiple drug resistance.
  • Origin
  • Phylogenetics
  • Epidemiology
  • Diversity
Session 3: Immunopathogenesis
The immune system helps in elimination of the invading microbial pathogens in the body through a series of defense mechanism. The innate immune response of the body provides first line of defense against the pathogens which is fast and non-specific response while adaptive immune response is specific and slow. The study of immunopathogenesis allows us to explore the disease transmission process, pathogen-host interactions, immune defense against the STD pathogens. This allows us to understand the pathological condition and progression of the disease and also the genetic factors influencing the immune defense against STD transmission. The genetic factors influence can be used for the development of gene therapies that triggers immune reaction against the disease-causing pathogens in the body.
  • Disease Transmission
  • Pathogen-Host Interaction
  • Innate Immune Response
  • Adaptive Immune Response
  • Genetic Factors
Session 4: Treatment Strategies
Antibiotics are used for treating the STDs caused by bacteria and protozoa. The bacterial STDs can be cured if the infection is properly diagnosed and treated. Several antibiotic resistant strains of pathogens have developed which pose a serious threat for health of the STD affected individuals. For viral STDs, there are no complete cure but progression of the disease can be controlled by antiretroviral therapies which use multiple antiretroviral drugs to decrease the disease proliferation and reduce other opportunistic infections. Gene therapy involves gene editing approaches which can provide a better and safer alternative to other existing drugs. Novel and emerging treatment strategies can provide a solution for the increasing drug resistance in the pathogens.
  • Antibiotic Therapy
  • Antiretroviral Combination Therapy
  • Immunotherapy
  • Gene Therapy

Session 5: STDs Prevention
Sexually Transmitted Diseases are transmitted from a person to another through sexual contact or blood transfusions from an infected person or needle sharing, or from mother to infant during pregnancy, labor and breastfeeding. STDs can be prevented through vaccination, screening and through promoting safer sexual behaviour, early health-care seeking behaviour, prevention and care activities. Pregnant women affected with STD must take proper treatment to prevent the vertical transmission of STD. Most STDs cannot be cured and leads to infertility, birth defects in infants, co-infections, opportunistic infections and many other health issues.
  • Effective Healthcare Systems
  • Vaccination
  • Preconception Care
  • Prenatal Care

Diagnosis of STDs are done by serological assays, amplification techniques, immunological diagnosis attains accurate result of the diagnosis. Point-of-care test enables rapid screening of Syphilis and allows treatment without delay. Nucleic acid amplification tests monitor the infection trends and helps in the adaptation of treatment protocols. Drug-resistance test provides the provisions for identifying drug resistance in the STDswhich aids in overcoming the resistance and provide a better treatment. Further improvements in the diagnosis method can help in rapid and cost-effective method for screening of the STDs.
  • Nucleic acid Tests
  • Serological Assays
  • Amplification Techniques
  • Immunological Diagnosis
  • Drug-Resistance Testing
  • Point- of-Care Test

Drug development and research is the development and invention of new drugs and improvement of existing drugs. Continuous progress in drug development and research field is necessary for invention of new drugs and drug targets for STDs. Identification of the drug target is the basis of the drug development process, this can be done through various computational approaches. Gene editing technology such as CRISPR seeks to eliminate the latent as well active HIV infection in the human which would be more effective in the treatment of AIDS. Various viral inhibitors such as entry inhibitors, maturation inhibitors are designed to inhibit the replication of the virus inside the host cell.
  • New Drugs and Drug Targets
  • Integrase Inhibitors
  • Entry Inhibitors
  • Maturation Inhibitors
  • Gene Editing
Session 8: Vaccines Development
A highly effective method for controlling infectious diseases is vaccination, it helps in prevention of high risk health issues. Prophylactic vaccines are those used for prevention while therapeutic vaccines are used for treatment of the specific disease. Sexually transmitted diseases are spread by pathogens such as bacteria, virus, fungi and protozoa. Many viral STDs doesn't have cure hence preventing the infection through vaccination is a best method. Vaccines are developed for Hepatitis and Human Papillomavirus (HPV) infection and for HIV and Herpes virus vaccines are being developed. Vaccination is the primary solution for eradication of sexually transmitted diseases in human.
  • Pre-Exposure Prophylaxis
  • Post-Exposure Prophylaxis
  • Therapeutic Vaccines
  • Advancements in Vaccine Technology
  • HIV and Genital herpes Vaccine Development

Nanotechnology is the science and engineering of structures that are 1–100 nm in size. Nanomedicine is a branch of medicine which is employed in preventive, diagnostic and therapeutic purposes. Using nanoparticles, effective timely release of drugs to the infected areas/organs are possible which improves specificity of drug action. HIV/AIDS patients face a major problem where the virus resides in latent reservoirs makes it hard to reach for drugs. Nanoparticles has the ability to travel through the body with less interruption which aids in effective release of drugs at HIV virus reservoirs at the specific target. Therapeutic nanoparticles have higher specificity for the drug targets which enhances the treatment efficiency and better cure for the affected individual.
  • Drug Delivery System
  • Drug Nanosuspension
  • Therapeutic Nanomaterials
  • Nanoparticle Based Vaccines

Plants contain a wide range of substances that are used for treating chronic as well as acute infectious diseases. Many modern drugs in use have been developed from the medicinal plants which has been used by indigenous people. Phytochemicals are chemicals secreted by plants that have disease preventive properties that is used by the plants to protect itself from diseases. Antimicrobial activity of the plant sources can act as a better drug for the strains that has developed multiple drug resistance to antibiotics. Many bacterial STDs can be combated using phytochemicals produced by the medicinal plants. Pharmacological effects of the bio active compounds in the plants must be explored to produce a cure for the multiple drug resistant bacterial STDs.
  • Antimicrobial Effect of Phytochemicals
  • Phytoconstituents and its Effects on STDs
  • Novel Therapeutic Drugs
  • Multi-Drug Resistance and Phytochemical Drugs

The infectious pathogens mutate under certain circumstances to overcome the pressure inflicted upon them. Such organisms develop resistance to the drug in use. This proves to be a major problem in the treatment of sexually transmitted diseases. Human immunodeficiency virus has developed resistance to the antiretroviral drug provided. Hence combination antiretroviral therapies are used for treating AIDS which involves using two or more antiretroviral drugs together. Several bacterial species has also developed resistance to the antibiotics provided for the treatment. The mutation of the pathogens has led to development of drug resistance against many antibiotics and antiretroviral drugs.
  • Nucleoside Reverse Transcriptase Inhibitors Resistance
  • Non-Nucleoside Reverse Transcriptase Inhibitors Resistance
  • Protease Inhibitors Resistance
  • Antibiotic Resistance
  • Antiviral Drug Resistance

Session 12: STDs and Cancer
Sexually transmitted diseases increases the risk of being affected by cancer. Among the STDs which lead to cancer, human papillomavirus infection is found to cause cervical cancer in women and penile cancer in men. It is also responsible for the development of oropharyngeal cancer in both sexes. Untreated STDs has a higher risk for leading to development of cancer. The progression of cancer in people affected by STD must be analyzed to understand the causative agents of the cancer.
  • Oropharyngeal Cancer
  • Cervical Cancer
  • Penile Cancer
  • Prostate Cancer
Session 13: Co-Infection of STDs
Gonorrhoea, chlamydia and trichomoniasis cause immune reactions which leads to inflammation that can easily be infected with HIV. Co-infection is a condition where a person actively infected with STD is infected with another STD. when a STI infected individual is prone to another infection due to immune compromise they are less able to mount a protective response against sexually transmitted pathogens. Treating co-infected individuals can be challenging and the treatment methods must be analyzed and modified to their needs.
  • HIV and Gonorrhea
  • HIV and Hepatitis
  • HIV and Kidney disease
  • HIV and Tuberculosis

When an STD infection is left untreated in women, it may be lead to pelvic inflammatory disease (PID). Being affected by pelvic inflammatory disease may lead to infertility or ectopic pregnancy in pregnant women. When the mother is infected by STD, the fetus or new born is mostly infected. STDs during pregnancy can lead to miscarriage, birth defects including blindness, deafness, bone deformities, and intellectual disability, stillbirth, premature birth. In males, reduced fertility or infertility is most common side effect of the disease.
  • Ectopic Pregnancy
  • Premature Birth
  • Neonatal Sepsis
  • Neurological Defects
Vertical STD transmission is the process of transfer of STD from a mother to infant perinatally or postnatally. During delivery, when the baby passes through the infected canal, it can contract the STDs such as chlamydia, gonorrhoea, genital herpes from the infected mother. Syphilis and HIV can be contracted from the mother during fetus development. Postnatal transmission of the disease is possible through breastfeeding the baby. Vertical STD transmission poses serious threat to the health of the baby.
  • Perinatal Transmission
  • Postnatal Transmission
  • Prevention of STD Transmission
  • Pregnancy Care and Treatment

Session 16: Paediatric STDs
Sexually Transmitted Diseases are an important cause of morbidity in paediatric patients. The transmission occurs via transplacental, intrapartum, and postpartum exposure. When an infant contracts STD from mother, it can affect the skin, eyes, mouth, central nervous system, and can also lead to organ failure. With treatment, the chances of transmitting HIV from mother to infant is low. Proper awareness, treatment and diagnosis is needed to prevent the transmission of STDs among young people.
  • Clinical Manifestation
  • Early Diagnosis
  • Risk Factors
  • Preventive Measures

Multi-morbidities is the presence of two or more chronic diseases at the same time. Super infection or re-infection is the condition where a person with HIV infection acquires infection with the sub-type of HIV. Re-infection affects the treatment which can deteriorate the health of the affected individual. The STDs affected individual suffers from other social and emotional complications which may also have adverse effects in the health of the individual. Multiple morbidities associated with the disease causes more damage to the health as the immune system would be compromised by the STD.
  • Opportunistic Infection
  • Superinfection/Reinfection
  • Behavioral Complications
  • Social Complications

Educational and awareness programs must be conducted to improve the public knowledge about the sexually transmitted diseases. People affected by sexually transmitted diseases have dramatically increased, millions of people are affected by the disease due to lack of awareness. Public must be aware about the impact of STDs on the lives of the affected people and the importance of preventing, screening and treating STDs. Poor knowledge about the STDs lead to increased health issues such as ectopic pregnancies, infertility and other complications. STDs are a major health issue that affects mostly young people, not only in developing countries but in developed countries also.
  • Impact of STDs
  • STD Screening
  • Risk Awareness
  • Prevention Education
  • Community Awareness

 

Monday, 16 July 2018

Antiviral Compound "Viperin" Found in the Human Body

The human body can make a compound with a special power to fight viruses; viperin is an enzyme made naturally in many mammals. Scientists have found that it has an antiviral effect on a variety of pathogens including hepatitis C, rabies and West Nile viruses. The enzyme aids the chemical reaction that generates ddhCTP, a molecule that can prevent viruses from replicating their genetic material, halting the expansion of the viral population. This work, which was reported in Nature, could have important implications in antiviral drug development.
"We knew viperin had broad antiviral effects through some sort of enzymatic activity, but other antivirals use a different method to stop viruses," explained study author Craig Cameron, a professor and the Eberly Chair in Biochemistry and Molecular Biology at Penn State. "Our collaborators at the Albert Einstein College of Medicine, led by senior authors Tyler Grove and Steven Almo, revealed that viperin catalyzes an important reaction that results in the creation of a molecule called ddhCTP. 
“Our team at Penn State then showed the effects of ddhCTP on a virus's ability to replicate its genetic material. Surprisingly, the molecule acts in a similar manner to drugs that were developed to treat viruses like HIV and hepatitis C. With a better understanding of how viperin prevents viruses from replicating, we hope to be able to design better antivirals."
Viruses usually have small genomes and lack critical cell components found in normal cells, so they hijack the cellular machinery they lack, using nucleotide bases from their host to build new genetic material - viral RNA. The ddhCTP chemical can mimic nucleotides, the foundations of DNA and RNA, and these 'nucleotide analogs' get incorporated into the new viral RNA that is made. Then they can interfere with the extension of the genetic strand, which stops the virus from making new copies of itself.
"Long ago, the paradigm was that in order to kill a virus, you had to kill the infected cell," said Cameron. "Such a paradigm is of no use when the virus infects an essential cell type with limited capacity for replenishment. The development of nucleotide analogs that function without actually killing the infected cell changed everything."
Usually, nucleotide analogs are synthetic and come with risks. Nucleotides are important in many ways, so they can have dangerous side effects.
"The major obstacle to developing therapeutically useful antiviral nucleotides is unintended targets," noted study author Jamie Arnold, associate research professor of biochemistry and molecular biology at Penn State. "For example, a few years ago we discovered that a nucleotide analog under development for [the] treatment of hepatitis C could interfere with the production of RNA in mitochondria, subcellular organelles important for energy production in the patient's own cells. That meant people with mitochondrial dysfunction are predisposed to any negative effects of this unintended interference."
However, ddhCTP appears to be safe so far; it does not seem to have unintended targets.
"Unlike many of our current drugs, ddhCTP is encoded by the cells of humans and other mammals," said Cameron. "We have been synthesizing nucleotide analogs for years, but here we see that nature beat us to the punch and created a nucleotide analog that can deal with a virus in living cells and does not exhibit any toxicity to date. If there's something out there that's going to work, nature has probably thought of it first. We just have to find it."
The researchers tested ddhCTP against West Nile, Zika and dengue viruses, and found that the ddhCTP could stop the replication of Zika in live cells.
"The molecule directly inhibited replication of three different strains of Zika virus," said study author Joyce Jose, assistant professor of biochemistry and molecular biology at Penn State. "It was equally effective against the original strain from 1947 as it was against two strains from the recent 2016 outbreak. This is particularly exciting because there are no known treatments for Zika. This study highlights a new avenue of research into natural compounds like ddhCTP that could be used in future treatments."
The researchers have shown that ddhCTP has a lot of potential as a therapeutic, although it was not effective against a class of viruses called picornaviruses; that group includes polio and rhinovirus. The researchers would like to find out why and determine if a vulnerable virus might gain resistance against ddhCTP.
"Development of resistance to an antiviral agent is always an issue," said Cameron, "Having some idea of how resistance happens, or being able to prevent it from happening, will be critical if this is to be used as a broad-spectrum therapy."
Source: https://www.labroots.com/trending/microbiology/11860/antiviral-compound-found-human-body
Call for abstracts: https://std-hiv-aids.cmesociety.com/call-for-abstracts
Abstract submission: https://std-hiv-aids.cmesociety.com/abstract-submission
Registration: https://std-hiv-aids.cmesociety.com/registration